Igor I. Slukvin

Igor Slukvin


Pathology & Laboratory Medicine

News Releases:

More information:

  • Additional appointments: Cell & Regenerative Biology (joint appointment); Wisconsin National Primate Center (affiliate scientist)
  • Slukvin Laboratory Home Page

Organ System/Disease Focus: 

Blood development/disease

Aligned Research Focus: 

Hematopoietic and endothelial development from human pluripotent stem cells, hematopoietic stem cell (HSC) biology

Research Description: 

Pluripotent stem (PS) cells, including embryonic stem (ES) and induced pluripotent stem (iPS) cells, represent a unique population of cells capable of self-renewal and differentiation. Pluripotent stem cells can form any cell type in the body and serve as a scalable cell source for transplantation and tissue engineering. The main focus of my research is to establish the differentiation of human pluripotent stem cells into hematopoietic progenitors and mature blood cells in order to understand molecular mechanisms of early hematopoietic differentiation and provide a novel source of cells for bone marrow transplantation, transfusion and cancer immunotherapy. Recently we developed methods for efficient differentiation of PS cells into myelomonocytic and erythroid cells and identified the hierarchy of mesodermal and hematoendothelial progenitors leading to the formation of blood cells and hematopoiesis-supportive elements.  In addition, we developed technologies for efficient reprogramming of normal and neoplastic blood cells into iPS cells. Currently my laboratory is working on 1) identification of genes essential for acquisition of long-term engraftment potential by pluripotent stem cell-derived hematopoietic cells; 2) establishing non-human primate models of ES cell and iPS cell-based cellular therapy for blood and immune system disorders; 3) developing iPS cell based models for blood cancer stem cell development.

Selected References: 

  • Kumar A, D’Souza SS, Moskvin OV, Toh H, Wang B, Zhang J, Swanson S, Guo LW, Thomson JA, Slukvin II., Specification and Diversification of Pericytes and Smooth Muscle Cells from Mesenchymoangioblasts. Cell Reports. 2017 May 30 [Epub ahead of print]
  • Slukvin II., Generating human hematopoietic stem cells in vitro -exploring endothelial to hematopoietic transition as a portal for stemness acquisition. FEBS Lett. 2016 Nov;590(22):4126-4143.
  • D'Souza SS, Maufort J, Kumar A, Zhang J, Smuga-Otto K, Thomson JA, Slukvin II., GSK3β Inhibition Promotes Efficient Myeloid and Lymphoid Hematopoiesis from Non-human Primate-Induced Pluripotent Stem Cells. Stem Cell Reports. 2016 Feb 9;6(2):243-56.
  • Kang H, Minder P, Park MA, Mesquitta WT, Torbett BE, Slukvin II., CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus. Mol Ther Nucleic Acids. 2015 Dec 15;4:e268.
  • Elcheva I, Brok-Volchanskaya V, Kumar A, Liu P, Lee JH, Tong L, Vodyanik M, Swanson S, Stewart R, Kyba M, Yakubov E, Cooke J, Thomson JA, Slukvin II., Direct induction of haematoendothelial programs in human pluripotent stem cells by transcriptional regulators. Nat Commun. 2014 Jul 14;5:4372.


Blood Research Program